Nuvectis Pharma, Inc. Common Stock (NVCT)

PHARMACEUTICAL PREPARATIONS

Nuvectis Pharma, Inc. Common Stock (NVCT) is listed on Nasdaq, where it has traded since February 4, 2022.

Listed On
Nasdaq
Listed Since
February 4, 2022
Employees
13
Market Cap
$660M

About Nuvectis Pharma, Inc. Common Stock

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 79 institutions reported holding NVCT, with 10.2 million shares worth $187.9 million in aggregate. The largest reported holder was Tang Capital Management, with 1.6 million shares worth $28.5 million. Of the 5 largest holders listed below, 3 opened new positions in NVCT and 2 added shares during the quarter.

InstitutionSharesValueQuarter change
Tang Capital Management1,550,000$29MNew position
Vanguard1,124,096$21MAdded 28.82%
BlackRock1,001,285$18MAdded 30.98%
Perceptive Advisors1,000,000$18MNew position
Soleus Capital Management,1,000,000$18MNew position

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions

What is NVCT?

Nuvectis Pharma, Inc. Common Stock (NVCT) is listed on Nasdaq, where it has traded since February 4, 2022.

Who are the largest institutional holders of NVCT?

In 13F filings for the quarter ended June 30, 2026, the largest reported holders of NVCT were Tang Capital Management, Vanguard and BlackRock.

How many institutions own NVCT?

79 institutions reported a position in NVCT for the quarter ended June 30, 2026, worth $187.9 million in total.

Did institutions buy or sell NVCT last quarter?

Of the 5 largest reported holders, 3 opened new positions in NVCT and 2 added shares during the quarter. Every reported holder and its change is on the SentiSense ownership page for NVCT.

Every reported institutional holder, plus insider and congressional trades in NVCT, on SentiSense.